Development, synthesis, and 68Ga-Labeling of a Lipophilic complexing agent for atherosclerosis PET imaging

European Journal of Medicinal Chemistry - Tập 176 - Trang 129-134 - 2019
Jennyfer Yong-Sang1,2, Fabienne Dioury2, Vincent Meneyrol3, Imade Ait-Arsa3, Jean-Patrick Idoumbin3, Florian Guibbal1, Jessica Patché1, Fanny Gimié3, Ilya Khantalin1,4, Joël Couprie1, Pierre Giraud1, Sébastien Benard3, Clotilde Ferroud2, Emmanuelle Jestin1,3, Olivier Meilhac1,4
1Université de La Réunion, Inserm, UMR 1188 Diabète Athérothrombose Thérapies Réunion Océan Indien (DéTROI), Plateforme CYROI, 2 rue Maxime Rivière, 97490, Sainte-Clotilde, Réunion, France
2Laboratoire de Génomique, Bioinformatique, et Chimie Moléculaire, EA 7528, Conservatoire national des Arts et métiers, 2 rue Conté, 75003, Paris, HESAM Université, France
3Groupe d’Intérêt Public, Cyclotron Réunion Océan Indien, 2 rue Maxime Rivière, 97490, Sainte-Clotilde, Réunion, France
4CHU de La Réunion, Allée des Topazes, 97400, Saint-Denis, Réunion, France

Tài liệu tham khảo

WHO, 2012 Lusis, 2000, Atherosclerosis, Nature, 407, 233, 10.1038/35025203 Shimizu, 2016, Recent advances in the development of PET/SPECT probes for atherosclerosis imaging, Nucl. Med. Mol. Imaging, 50, 284, 10.1007/s13139-016-0418-9 Kuai, 2016, High-Density lipoproteins: nature's multifunctional nanoparticles, ACS Nano, 10, 3015, 10.1021/acsnano.5b07522 Perez-Medina, 2016, In vivo PET imaging of HDL in multiple atherosclerosis models, JACC Cardiovasc. Imaging, 9, 950, 10.1016/j.jcmg.2016.01.020 Cormode, 2009, HDL as a contrast agent for medical imaging, Clin. Lipidol., 4, 493, 10.2217/clp.09.38 Cormode, 2008, An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection, Small, 4, 1437, 10.1002/smll.200701285 Cormode, 2009, Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis, Bioconjug. Chem., 20, 937, 10.1021/bc800520d Rudd, 2002, Imaging atherosclerotic plaque inflammation with [18F]-Fluorodeoxyglucose Positron emission Tomography, Circulation, 105, 2708, 10.1161/01.CIR.0000020548.60110.76 Ferreira, 2010, Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals, Bioconjug. Chem., 21, 531, 10.1021/bc900443a Blom, 2012, 68Ga-autoclabeling of DOTA-TATE and DOTA-NOC, Int. J. Appl. Radiat. Isot., 70, 980, 10.1016/j.apradiso.2012.03.032 Lattuada, 2011, The synthesis and application of polyamino polycarboxylic bifunctional chelating agents, Chem. Soc. Rev., 40, 3019, 10.1039/c0cs00199f Spang, 2016, Bifunctional gallium-68 chelators: past, present, and future, Semin. Nucl. Med., 46, 373, 10.1053/j.semnuclmed.2016.04.003 Hak, 2009, A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging, Eur. J. Pharm. Biopharm., 72, 397, 10.1016/j.ejpb.2008.09.017 Dioury, 2005, Synthesis of a new tricyclic tetraazatriacetic acid as ligand for gadolinium(III), Tetrahedron Lett., 46, 611, 10.1016/j.tetlet.2004.11.133 Ferreira, 2012, 68Ga small peptide imaging: comparison of NOTA and PCTA, Bioconjug. Chem., 23, 2239, 10.1021/bc300348d Chakravarty, 2011, Development of a nano-zirconia based 68Ge/68Ga generator for biomedical applications, Nucl. Med. Biol., 38, 575, 10.1016/j.nucmedbio.2010.10.007 Ferroud, 2008, Synthesis of a novel amphiphilic GdPCTA-[12] derivative as a potential micellar MRI contrast agent, Tetrahedron Lett., 49, 5972, 10.1016/j.tetlet.2008.07.160 Enel, 2018, Facile access to the 12-membered macrocyclic ligand PCTA and its derivatives with carboxylate, amide, and phosphinate ligating functionalities, Eur. J. Org. Chem., 2018, 1765, 10.1002/ejoc.201800066 Ortiz-Muñoz, 2009, HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property, FASEB J., 23, 3129, 10.1096/fj.08-127928 Bartneck, 2014, Therapeutic targeting of liver inflammation and fibrosis by nanomedicine, Hepatobiliary Surg. Nutr., 3, 364 Tricoci, 2015, Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial, J. Am. Heart Assoc., 4, e002171, 10.1161/JAHA.115.002171